Loading…
Loading…
DHSC maintains a standing list of medicines subject to a domestic-supply-protection export restriction under regulation 43(2) of the Human Medicines Regulations 2012, revised on a rolling basis as shortage risk shifts across products (same standing mechanism as the November 2025 Nelarabine revision and the January 2026 Aspirin/Ifosfamide revision already in the register — see uk-medicines-export-control-architecture theme).
The 17 July 2025 revision added a first-line tuberculosis-treatment combination to the list: Rifampicin (standalone and in fixed-dose combinations with Isoniazid and Pyrazinamide), Pyrazinamide standalone, and the branded fixed-dose combination Voractiv. TB treatment regimens depend on uninterrupted multi-drug supply, so a shortage risk across this cluster of core anti-TB antimicrobials is a more acute patient-safety signal than a single-product listing. Trade press attributed the addition to global rifampicin/TB-drug supply pressure rather than a UK-specific manufacturing incident. The restriction took effect the same day it was announced.
its standing lever for shortage-risk management, now extended to essential-medicines / infectious-disease treatment classes rather than only chronic-disease or oncology products.
underlying supply pressure spans the rifampicin/isoniazid/pyrazinamide production chain, not one manufacturer.
ingredient supplier or geography; global rifampicin API production is concentrated in a small number of Indian and Chinese manufacturers, but this action's primary source does not name one.